Analyst Expects Roche’s Newly FDA-Cleared Insulin Patch Pump Will Have ‘Limited Impact’
Roche received FDA clearance for its Solo insulin patch pump, but is expected to face significant barriers to entry in the highly competitive US insulin pump market.
You may also be interested in...
The complaint says that EOFlow developed its EOPatch insulin delivery system with the help of former Insulet employees and Insulet’s contract manufacturer. Medtronic announced plans to acquire EOFlow in May, and US FDA clearance is on the horizon.
Insulet will acquire insulin pump patents from Bigfoot Biomedical for $25m, which Bigfoot will use to expand its Unity diabetes management system. Insulet also announced the acquisition of automated insulin delivery assets held by Automated Glucose Control.
Harbinger Health has raised a total of $190m since its founding in 2021. Its CEO Stephen Hahn told Medtech Insight in March that the company plans to develop a blood-based cancer test that is affordable, accessible and also more accurate than currently available tests.